Degradation of the NOTCH intracellular domain by elevated autophagy in osteoblasts promotes osteoblast differentiation and alleviates osteoporosis.
Gota YoshidaTsuyoshi KawabataHyota TakamatsuShotaro SaitaShuhei NakamuraKeizo NishikawaMari FujiwaraYusuke EnokidaniTadashi YamamuroKeisuke TabataMaho HamasakiMasaru IshiiAtsushi KumanogohTamotsu YoshimoriPublished in: Autophagy (2022)
Maintenance of bone integrity is mediated by the balanced actions of osteoblasts and osteoclasts. Because macroautophagy/autophagy regulates osteoblast mineralization, osteoclast differentiation, and their secretion from osteoclast cells, autophagy deficiency in osteoblasts or osteoclasts can disrupt this balance. However, it remains unclear whether upregulation of autophagy becomes beneficial for suppression of bone-associated diseases. In this study, we found that genetic upregulation of autophagy in osteoblasts facilitated bone formation. We generated mice in which autophagy was specifically upregulated in osteoblasts by deleting the gene encoding RUBCN/Rubicon, a negative regulator of autophagy. The <i>rubcn<sup>flox/flox</sup>;Sp7/Osterix-Cre</i> mice showed progressive skeletal abnormalities in femur bones. Consistent with this, RUBCN deficiency in osteoblasts resulted in elevated differentiation and mineralization, as well as an increase in the elevated expression of key transcription factors involved in osteoblast function such as <i>Runx2</i> and <i>Bglap/Osteocalcin</i>. Furthermore, RUBCN deficiency in osteoblasts accelerated autophagic degradation of NOTCH intracellular domain (NICD) and downregulated the NOTCH signaling pathway, which negatively regulates osteoblast differentiation. Notably, osteoblast-specific deletion of RUBCN alleviated the phenotype in a mouse model of osteoporosis. We conclude that RUBCN is a key regulator of bone homeostasis. On the basis of these findings, we propose that medications targeting RUBCN or autophagic degradation of NICD could be used to treat age-related osteoporosis and bone fracture.<b>Abbreviations</b>: ALPL: alkaline phosphatase, liver/bone/kidney; BCIP/NBT: 5-bromo-4-chloro-3'-indolyl phosphate/nitro blue tetrazolium; BMD: bone mineral density; BV/TV: bone volume/total bone volume; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NICD: NOTCH intracellular domain; RB1CC1/FIP200: RB1-inducible coiled-coil 1; RUBCN/Rubicon: RUN domain and cysteine-rich domain containing, Beclin 1-interacting protein; SERM: selective estrogen receptor modulator; TNFRSF11B/OCIF: tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin).
Keyphrases
- bone mineral density
- postmenopausal women
- signaling pathway
- cell death
- body composition
- endoplasmic reticulum stress
- bone loss
- bone regeneration
- induced apoptosis
- oxidative stress
- cell proliferation
- transcription factor
- cell cycle arrest
- mouse model
- pi k akt
- rheumatoid arthritis
- estrogen receptor
- soft tissue
- genome wide
- multiple sclerosis
- immune response
- gene expression
- replacement therapy
- inflammatory response
- dna methylation
- metabolic syndrome
- tyrosine kinase
- lps induced
- dna binding
- smoking cessation